EGFR and non-small cell lung carcinoma: Since the approval of EGFR TKIs considerably reshaped the therapeutic landscape of NSCLC over the last decade [57, 58], we focused on six NSCLC models expressing either wild-type EGFR (i.e. A549, EBC-1 and H1993) or EGFR-mutated forms (i.e. HCC827, H1975 and PC9) (Table S3).